

FOR IMMEDIATE RELEASE

AMNEAL SUCCESSFULLY COMPLETES TECHNOLOGY/SITE TRANSFERS FOR ACEBUTOLOL AND FLECAINIDE

Hauppauge, NY (USA), March 1, 2009 – Amneal Pharmaceuticals is pleased to announce that it has successfully completed approval of the technology and site transfers of Acebutolol Hydrochloride Capsules (200mg, 400mg) and Flecainide Acetate Tablets (50 mg, 100 mg, 150 mg). Executing the asset purchase agreement following its acquisition of five ANDAs from Merck kGa in October 2007 triggered the manufacturing transfer of these two products to Amneal's facilities.

Acebutolol HCl is an AB-rated, therapeutically equivalent alternative to Sectral® (a trademark of Rhone-Poulenc Industries) and is indicated for the management of hypertension in adults and in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats.

Flecainide acetate is an AB-Rated, therapeutically equivalent alternative to Tambocor® (a trademark of Riker Laboratories, Inc.) and in patients without structural heart disease, it is indicated for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.

Amneal will begin shipping flecainide acetate in 50 mg, 100 mg and 150 mg strengths as of March 2, 2009. Since approval was granted December 1, 2008 for acebutolol, Amneal is already shipping this product in the 200 mg and 400 mg strengths. Both acebutolol and flecainide, along with Amneal's full line of generic pharmaceutical products, will be available through wholesalers-distributors as well as directly to the trade.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufactures and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.

###

CONTACT: Jim Luce, Executive Vice President-Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Mobile: 949-633-2293
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
Corporate Headquarters
85 Adams Avenue
Hauppauge, NY 11788